Improvements of cellular stress response on resveratrol in liposomes.

Department of Pharmacy, University of Ljubljana, Askerceva7, Ljubljana 1000, Slovenia.
European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V (Impact Factor: 3.15). 07/2009; 73(2):253-9. DOI: 10.1016/j.ejpb.2009.06.006
Source: PubMed

ABSTRACT Resveratrol (RSV) has proven potential in prophylaxis and treatment of various disorders mediated by free radicals and oxidative stress. RSV solubility, stability, and cytotoxicity must be regulated for satisfactory bioavailability. Here, RSV was loaded into liposomes, characterized by PCS and TEM and evaluated on HEK293 cell line by metabolic activity assay, electron paramagnetic resonance, and fluorescence microscopy. RSV at 10 microM induced changes in cell metabolic activity and significantly improved antioxidative capacity. At 100 microM it showed concentration-dependent cytotoxicity. Oligolamellar liposomes with mean diameter 84 nm, polydispersity index 0.2, and zeta potential -40 mV showed high entrapment of RSV and rapid cellular internalization. Cell stress caused by UV-B irradiation diminished cell metabolic activity by 50%. RSV loaded into them showed no cytotoxicity at 100 microM and stimulated cellular metabolic and antioxidant activity levels to eliminate the harmful effect of the stress. Localization of RSV within liposomal bilayer is crucial for stimulation of cell-defense system, prevention of RSV cytotoxicity, and its long-term stability. In summary, evidence of different metabolic activity using free RSV and LIP-RSV is presented indicating that liposome-mediated uptake of RSV is more effective for improvement of the cell-stress response.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Trans-resveratrol (t-RVT) is a potent antioxidant. The drug suffers enterohepatic recirculation and extensive first-pass metabolism by CYP3A4 in liver, resulting in very low bioavailability (almost zero). Objective: The current studies entail a novel formulation approach to develop systematically optimized (OPT) nanoparticles (NPs) to enhance the oral bioavailability potential using poly (dl-lactide-co-glycolide) (PLGA) of t-RVT and overcome enterohepatic recirculation. Methods: T-RVT-loaded PLGA NPs were prepared by nanoprecipitation method. Delineating the NP regions, the amounts of polymer and emulsifier were selected as the critical factors for systematically formulating the OPT NPs employing 3(2) central composite design. The pharmacokinetics, in vivo biodistribution and in situ single-pass intestinal perfusion (SPIP) studies of OPT formulation were investigated in male Wistar rats. Results: Augmentation in the values of Ka (7.17-fold) and AUC0 - ∞ (10.6-fold) indicated significant enhancement in the rate and extent of bioavailability by the OPT formulation compared to pure drug and marketed product. OPT formulation showed a 2.78-fold rise in the values of t-RVT concentrations in liver. In situ SPIP studies ascribed the significant enhancement in absorptivity and permeability parameters of OPT NPs to transport through the Peyer's patches. Successful establishment of in vitro/in vivo correlation substantiated the judicious choice of the in vitro dissolution milieu for simulating the in vivo conditions. Conclusion: The studies, therefore, could provide another useful tool for successful development of t-RVT NPs and an in vivo approach to designate nanoparticulate system of t-RVT with distinctly improved bioavailability and to overcome enterohepatic recirculation.
    Expert Opinion on Drug Delivery 03/2014; · 4.87 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Context: Quercetin (QUE) is a flavonoid with antioxidant/anti-inflammatory properties, poorly absorbed when orally administered. Objectives: To prepare chitosan/xanthan gum microparticles to increase QUE oral bioavailability and optimize its release in the colon. Materials and methods: Chitosan/xanthan gum hydrogel embedding QUE was spray-dried to obtain microparticles characterized by size, scanning electron microscopy, differential scanning calorimetry and X-ray diffraction. Microparticles were compressed into tablets, coated with Eudragit® to further prevent degradation in acidic pH. The swelling degree and QUE release in simulated gastric and intestinal pH were investigated. Results: Microparticles were smooth and spherical, around 5 µm, with successful QUE loading. Microparticle tablets provided resistance to acidic conditions, allowing complete drug release in alkaline pH, mimicking colonic environment. The release was controlled by non-Fickian diffusion of the dissolved drug out of the swollen polymeric tablet. Discussion and conclusion: Microparticle tablets represent a promising dosage form for QUE delivery to the colon in the oral therapy of inflammatory-based disorders.
    Journal of Microencapsulation 06/2014; · 1.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives The current studies entail successful formulation of systematically optimized (OPT) nanoparticulate drug delivery system to increase the oral bioavailability using Eudragit RL 100 of trans-resveratrol (t-RVT), and evaluate their in-vitro/in-vivo performance.Methodst-RVT-loaded Eudragit RL 100 nanoparticles (t-RVT NPs) were prepared by nanoprecipitation method. The nanoparticles (NPs) were systematically optimized using 32 central composite design and the OPT formulation located using overlay plot. The pharmacokinetic and in-vivo biodistribution of t-RVT NPs were investigated in rats, and various levels of in-vitro/in-vivo correlation (IVIVC) were established.Key findingsThe OPT formulation (mean particle size: 180 nm) indicated marked improvement in drug release profile vis-à-vis pure drug and marketed formulation (MKT). Augmentation in the values of Ka (5.64-fold) and AUC0–24 (7.25-fold) indicated significant enhancement in the rate and extent of bioavailability by the optimized trans-resveratrol-loaded Eudragit RL 100 nanoparticles (OPT-t-RVT NPs) compared with pure drug. Level A of IVIVC was successfully established. OPT-t-RVT NPs showed 4.11-fold rose in the values of t-RVT concentrations in liver. In-situ single pass intestinal perfusion studies construed remarkable enhancement in the absorptivity and permeability parameters of OPT-t-RVT NPs.Conclusions The results, therefore, insight into the role of solubility enhancement and trounce enterohepatic recirculation for improving the oral bioavailability of t-RVT.
    Journal of Pharmacy and Pharmacology. 05/2014;


Available from
May 16, 2014